Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - rasagiline tartrate - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - rasagiline tartrate - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Marekani - Kiingereza - NLM (National Library of Medicine)

indoco remedies limited - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline tablets are contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)]. at least 14 days should elapse between discontinuation of rasagiline tablets and initiation of treatment with these medications. rasagiline tablets are contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline tablets are contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the development risk associate with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically.

Marekani - Kiingereza - NLM (National Library of Medicine)

avkare - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions ( 5.2)] . at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. rasagiline is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: maize starch; purified talc; stearic acid; microcrystalline cellulose; pregelatinised maize starch; citric acid monohydrate; colloidal anhydrous silica - rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Marekani - Kiingereza - NLM (National Library of Medicine)

micro labs limited - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) -   rasagiline tablets are indicated for the treatment of parkinson's disease (pd). rasagiline tablet is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of rasagiline tablet and initiation of treatment with these medications. rasagiline tablet is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline tablet is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses si

Marekani - Kiingereza - NLM (National Library of Medicine)

alvogen, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. rasagiline is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to pregnant animals in com

Marekani - Kiingereza - NLM (National Library of Medicine)

avet pharmaceuticals inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline tablets are contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)]. at least 14 days should elapse between discontinuation of rasagiline tablets and initiation of treatment with these medications. rasagiline tablets are contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline tablets are contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risk associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinical

Marekani - Kiingereza - NLM (National Library of Medicine)

uriel pharmacy inc. - hamamelis virginiana top (unii: uda30a2jjy) (hamamelis virginiana top - unii:uda30a2jjy) - hamamelis virginiana top 3 [hp_x] in 1 ml - directions: for oral use. use: temporary relief of burns.